Press Releases

10.17.25

Press Release

Achieve Life Sciences Receives FDA Commissioner’s National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British Columbia, October 17, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development…

/Read More

10.02.25

Press Release

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, October 2, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve’s board of directors approved stock option grants to…

/Read More

09.22.25

Press Release

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges SEATTLE and VANCOUVER, British Columbia, September 22, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as treatment of nicotine dependence, today…

/Read More

09.18.25

Press Release

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations  SEATTLE and VANCOUVER, British Columbia, September 18, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced…

/Read More

09.11.25

Press Release

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

SEATTLE and VANCOUVER, British Columbia, September 11, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr….

/Read More